148 related articles for article (PubMed ID: 38839666)
1. Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.
Dong L; Hu C; Ma Z; Huang Y; Shelley G; Kuczler MD; Kim CJ; Witwer KW; Keller ET; Amend SR; Xue W; Pienta KJ
Med Oncol; 2024 Jun; 41(7):169. PubMed ID: 38839666
[TBL] [Abstract][Full Text] [Related]
2. Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.
Dong L; Hu C; Ma Z; Huang Y; Shelley G; Kuczler MD; Kim CJ; Witwer KW; Keller ET; Amend SR; Xue W; Pienta KJ
Res Sq; 2024 Mar; ():. PubMed ID: 38585988
[TBL] [Abstract][Full Text] [Related]
3. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
4. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
5. Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.
Koppers-Lalic D; Hackenberg M; de Menezes R; Misovic B; Wachalska M; Geldof A; Zini N; de Reijke T; Wurdinger T; Vis A; van Moorselaar J; Pegtel M; Bijnsdorp I
Oncotarget; 2016 Apr; 7(16):22566-78. PubMed ID: 26992225
[TBL] [Abstract][Full Text] [Related]
6. Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients.
Ramirez-Garrastacho M; Berge V; Linē A; Llorente A
Br J Cancer; 2022 Feb; 126(3):492-501. PubMed ID: 34811506
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity.
Tafuri A; Rizzetto R; Amigoni N; Sebben M; Shakir A; Gozzo A; Odorizzi K; Gallina S; Bianchi A; Ornaghi P; Brunelli M; Migliorini F; Cerruto MA; Artibani W; Siracusano S; Antonelli A; Porcaro AB
Urol Int; 2021; 105(5-6):362-369. PubMed ID: 33059351
[TBL] [Abstract][Full Text] [Related]
8. Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection.
Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Montorsi F; Saad F; Briganti A; Steuber T; Budäus L; Huland H; Graefen M; Tilki D; Karakiewicz PI
Urol Oncol; 2018 Aug; 36(8):365.e1-365.e7. PubMed ID: 29887241
[TBL] [Abstract][Full Text] [Related]
9. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle-invasive bladder cancer.
Baumgart S; Meschkat P; Edelmann P; Heinzelmann J; Pryalukhin A; Bohle R; Heinzelbecker J; Stöckle M; Junker K
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2725-2736. PubMed ID: 31552489
[TBL] [Abstract][Full Text] [Related]
12. Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer.
Bryzgunova OE; Zaporozhchenko IA; Lekchnov EA; Amelina EV; Konoshenko MY; Yarmoschuk SV; Pashkovskaya OA; Zheravin AA; Pak SV; Rykova EY; Laktionov PP
PLoS One; 2019; 14(4):e0215003. PubMed ID: 30970027
[TBL] [Abstract][Full Text] [Related]
13. Systematic Analysis of Tissue-Derived and Biofluid Extracellular Vesicle miRNAs Associated with Prostate Cancer.
Larson J; Ozen MO; Kohli M; Akin D; Demirci U
Adv Biol (Weinh); 2023 Jul; 7(7):e2200327. PubMed ID: 37300338
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
15. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Fossati N; Stabile A; Beauval JB; Malavaud B; Roumiguié M; Robesti D; Dell'Oglio P; Moschini M; Zamboni S; Rakauskas A; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
Eur Urol; 2019 Mar; 75(3):506-514. PubMed ID: 30342844
[TBL] [Abstract][Full Text] [Related]
16. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
Briganti A; Abdollah F; Nini A; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni NM; Salonia A; Colombo R; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610
[TBL] [Abstract][Full Text] [Related]
17. Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer.
Porcaro AB; De Luyk N; Corsi P; Sebben M; Tafuri A; Processali T; Mattevi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli MA; Migliorini F; Siracusano S; Artibani W
Urol Int; 2017; 99(4):392-399. PubMed ID: 28486228
[TBL] [Abstract][Full Text] [Related]
18. A clinicogenetic model to predict lymph node invasion by use of genome-based biomarkers from exome arrays in prostate cancer patients.
Oh JJ; Park S; Lee SE; Hong SK; Lee S; Lee HM; Lee JK; Ho JN; Yoon S; Byun SS
Korean J Urol; 2015 Feb; 56(2):109-16. PubMed ID: 25685297
[TBL] [Abstract][Full Text] [Related]
19. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
20. Challenges in Cancer Biomarker Discovery Exemplified by the Identification of Diagnostic MicroRNAs in Prostate Tissues.
Ambrozkiewicz F; Karczmarski J; Kulecka M; Paziewska A; Cybulska M; Szymanski M; Dobruch J; Antoniewicz A; Mikula M; Ostrowski J
Biomed Res Int; 2020; 2020():9086829. PubMed ID: 32462034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
